RxDoctor Payments Data

Jean Tan, MD

Internal Medicine · Franklin, TNNPI 1982689279

Payments from drug & device makers

$11,708in general payments, 2019–2025

Across 711 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$921
  • Boehringer Ingelheim$605
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$11,670100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,708 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$67,081
Medicare patients
234
Services billed
1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide233$236,010
JardianceEmpagliflozin203$148,384
MounjaroTirzepatide131$143,203
EliquisApixaban100$82,283
Tresiba Flextouch U-200Insulin Degludec62$71,241
Synjardy XrEmpagliflozin/Metformin Hcl54$58,732
VascepaIcosapent Ethyl68$41,156
TrulicityDulaglutide24$35,566
FarxigaDapagliflozin Propanediol42$34,764
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$23,407
Repatha SureclickEvolocumab24$19,727
MyrbetriqMirabegron29$18,590
LinzessLinaclotide22$16,483
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide233$14,612
Valsartan364$14,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,844$236,010233 claims
Boehringer IngelheimJardiance, Synjardy Xr$605$207,116257 claims
Lilly USA, LLCMounjaro, Trulicity$1,037$178,768155 claims
PfizerEliquis$605$82,283100 claims
GSKTrelegy Ellipta, Breo Ellipta$278$36,16243 claims
AstraZenecaFarxiga$1,064$34,76442 claims
Astellas Pharma US IncMyrbetriq$18$18,59029 claims
AbbVieLinzess$1,142$16,48322 claims
ANI Pharmaceuticals, Inc.Valsartan$28$14,110364 claims
Sumitomo Pharma America, Inc.Gemtesa$32$11,97812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →